Certara, Inc. (CERT) — ESG & Values Scores

Environment story

Certara discloses minimal direct environmental metrics. No Scope 1, 2, or 3 GHG emissions data, renewable energy percentage, or net-zero target year are disclosed in the 10-K or MD&A. The company operates a software and consulting services business with limited physical operations (offices in 14 countries, cloud-hosted infrastructure via third-party providers), suggesting relatively low operational carbon footprint compared to heavy manufacturing or extraction. However, absence of quantified emissions reporting, net-zero commitments, and climate targets results in a baseline deduction. The company acknowledges emerging regulatory disclosure obligations (EU CSRD, California climate laws) but provides no evidence of current GHG accounting or decarbonization initiatives. Risk disclosures indicate awareness of climate-related regulatory risks but no proactive mitigation or transparency.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Cloud Infrastructure via Third-Party Providers

Company outsources substantially all hosted software infrastructure to third-party cloud providers, reducing direct operational carbon footprint compared to on-premises hosting.

Indirect reduction in Scope 2 emissions; responsibility for provider emissions transparency delegated.
Regulatory Disclosure Readiness

10-K acknowledges potential future obligations under EU CSRD and California climate disclosure laws; company states it 'may become subject' to these frameworks and expects to incur costs for 'due diligence, verification and reporting in connection with sustainability initiatives.'

Indicates awareness of climate reporting standards but no current commitments or targets announced.

Social story

Certara employs 414+ Ph.D. or M.D. holders as of December 31, 2025, reflecting high-skill workforce. No CEO-to-worker pay ratio disclosed; no documented union suppression activities, strikes, or major labor disputes in the last 24 months identified in 10-K. Diversity metrics for executive and board leadership are not disclosed. The company acknowledges dependence on 'highly qualified personnel' and competitive compensation requirements; industry-standard high turnover risk disclosed but not quantified. No documented supply-chain human-rights audits, modern slavery statements, or supply-chain ethics controversies identified. Workforce-related risks noted (immigration visa constraints, independent contractor reclassification risk) but no active labor violations disclosed. The company acquired multiple businesses (Chemaxon, Formedix, ABM, DIDB) with post-acquisition integration workforce risks but no evidence of labor disputes arising from these integrations.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Ph.D./M.D. Workforce Development

As of December 31, 2025, 414 employees held Ph.D. or M.D. degrees; company invests in recruiting and retaining highly qualified scientists for R&D, modeling, and regulatory expertise.

Positions company as talent-intensive, suggesting investment in human capital development and competitive compensation.
Academic Partnerships & Training Pipeline

Company works with global academic institutions on research and training of next-generation biopharmaceutical scientists; offers software free or at reduced cost to academic institutions to build familiarity and future talent pipeline.

Supports workforce development and social contribution; creates positive reputation among academic communities.
International Workforce & Visa Sponsorship

Company recruits skilled professionals internationally and sponsors visas; operations span 14 countries (US, Canada, France, Germany, Netherlands, Poland, Switzerland, UK, India, Philippines, Japan, China, Hungary, South Korea).

Indicates commitment to global talent acquisition and diversity; acknowledges visa constraints as business risk.

Governance story

Certara's 10-K does not disclose board independence percentage, executive compensation ratios, or board composition details. No dual-class share structure is evident from filings. The company is party to a Credit Agreement (most recently amended October 16, 2025) with covenants; management states compliance with all covenants as of December 31, 2025. No evidence of material antitrust proceedings, SEC consent decrees, significant privacy fines, or shareholder litigation disclosed. The company acknowledges lobbying exposure and compliance with FCPA and UK Bribery Act but provides no quantified annual lobbying spend or PAC contribution disclosures in the 10-K excerpt. Government contracting revenues (FDA, CDC, foreign regulatory agencies license software) expose company to government audit and compliance risks; 20 regulatory agencies globally license Certara products. No shareholder proposals, board independence metrics, or governance disputes disclosed. Risk disclosures include potential future liability for AI governance, data privacy, and export control violations but no current enforcement actions identified.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Credit Agreement Compliance & Covenant Management

Company maintains compliance with covenants under senior secured Credit Agreement (Term Loan $295.5M, Revolving Facility $100M, both amended as of October 2025). Maturity dates: Term Loan June 26, 2031; Revolving Facility June 26, 2029.

Demonstrates active debt management and regulatory compliance; no covenant violations disclosed.
Government Contract Compliance & Regulatory Licensing

Software products licensed by 20 global regulatory agencies (FDA, PMDA, NMPA, MHRA, others). Company subjects itself to FDA inspection, GLP/GCP standards, and compliance with 21 CFR Part 11 (electronic records). Acknowledges exposure to False Claims Act and potential debarment from government contracting.

Demonstrates commitment to regulatory compliance; establishes governance framework for government-facing services.
FCPA and Anti-Corruption Compliance

Company states officers, directors, employees, and agents are subject to internal policies and FCPA/UK Bribery Act compliance training. Global operations in 14 countries with diverse regulatory regimes.

Indicates governance infrastructure for international compliance; acknowledges risk of third-party violations despite controls.
AI Governance Framework

Company explicitly states 'expert-in-the-loop model' for AI deployment, emphasizing 'validation of scientific frameworks and expert-led workflows' rather than standalone automated systems. Aims to ensure 'transparency, reproducibility, and explainability' consistent with regulatory expectations.

Demonstrates governance attention to AI risk; commits to scientific rigor and regulatory alignment in AI product development.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Certara, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Certara, Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)